The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes

被引:49
作者
Berger, WE
Legorreta, AP
Blaiss, MS
Schneider, EC
Luskin, AT
Stempel, DA
Suissa, S
Goodman, DC
Stoloff, SW
Chapman, JA
Sullivan, SD
Vollmer, B
Weiss, KB
机构
[1] Hlth Benchmarks, Woodland Hills, CA 91367 USA
[2] Amer Coll Allergy Asthma & Immunol, Mission Viejo, CA USA
[3] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA
[4] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA
[5] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA
[6] McGill Univ, Montreal, PQ, Canada
[7] Royal Victoria Hosp, Montreal, PQ, Canada
[8] Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci, Hanover, NH USA
[9] Univ Nevada, Sch Med, Reno, NV 89557 USA
[10] Univ Washington, Dept Pharm, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA
[11] Kaiser Permanente Ctr Hlth Res, Portland, OR USA
[12] Hines VA Hosp, Midwest Ctr Hlth Serv & Policy Res, Chicago, IL USA
[13] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA
[14] Northwestern Univ, Feinberg Sch Med, Div Gen Med, Chicago, IL 60611 USA
[15] Dean Med Ctr, Madison, WI USA
[16] INFOMED Northwest, Bellevue, WA USA
关键词
D O I
10.1016/S1081-1206(10)61260-4
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: The Health Plan Employer Data and Information Set (HEDIS) measures are used extensively to measure quality of care. Objective: To evaluate selected aspects of the HEDIS measure of appropriate use of asthma medications. Methods: Claims data were analyzed for commercial health plan members who met HEDIS criteria for persistent asthma in 1999. The use of asthma medications was evaluated in the subsequent year with stratification by controller medication and a measure of adherence (days' supply). Multivariate logistic regressions were used to evaluate the association among long-term controller therapy for persistent asthma, adherence to therapy, and asthma-related hospitalizations or emergency department (ED) visits, controlling for demographic, preindex utilization, and other confounding characteristics. Results: Of the 49,637 persistent asthma patients, approximately 35.7% were using 1 class of long-term controller medications, 18.4% were using more than 1 class, and 45.9% were not using such medication. More than 25% of the persistent asthma patients did not use any asthma medication in the subsequent year. Patients with low adherence to controller medication had a significantly higher risk (odds ratio [OR], 1.72; 95% confidence interval [CI], 1.42-2.08) of ED visit or hospitalization relative to patients not using any controllers compared with persons with moderate (OR, 0.84; 95% CI, 0.57-1.23) or high (OR, 0.70; 95% CI, 0.34-1.44) adherence. Patients receiving a high days' supply of inhaled corticosteroids had the lowest risk of ED visit or hospitalization (OR, 0.37; 95% CI, 0.05-2.69). Conclusions: Our findings suggest that refinements to the HEDIS measure method for identifying patients with persistent asthma may be needed.
引用
收藏
页码:538 / 545
页数:8
相关论文
共 44 条
[1]  
*AM MED ASS, 1999, CURR PROC TERM
[2]  
[Anonymous], 2001, INT CLASSIFICATION D
[3]   Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma [J].
Bleecker, ER ;
Welch, MJ ;
Weinstein, SF ;
Kalberg, C ;
Johnson, M ;
Edwards, L ;
Rickard, KA .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 105 (06) :1123-1129
[4]  
Bost J E, 2001, Manag Care Interface, V14, P50
[5]   Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma [J].
Busse, W ;
Nelson, H ;
Wolfe, J ;
Kalberg, C ;
Yancey, SW ;
Rickard, KA .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 103 (06) :1075-1080
[6]   Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial [J].
Busse, W ;
Raphael, GD ;
Galant, S ;
Kalberg, C ;
Goode-Sellers, S ;
Srebro, S ;
Edwards, L ;
Rickard, K .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (03) :461-468
[7]   Asthma variability in patients previously treated with β2-agonists alone [J].
Calhoun, WJ ;
Sutton, LB ;
Emmett, A ;
Dorinsky, PM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 112 (06) :1088-1094
[8]  
Chung Richard S, 2003, J Healthc Qual, V25, P31
[9]  
Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566
[10]  
DUCHARME FM, 2002, COCHRANE DATABASE SY